EXEL director granted 8,367 RSUs in equity award

PAPADOPOULOS STELIOS reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

PAPADOPOULOS STELIOS reported acquisition or exercise transactions in this Form 4 filing.

EXELIXIS, INC. director Stelios Papadopoulos received an equity award in the form of 8,367 restricted stock units, each equivalent to one share of common stock. The grant was made at no cash cost to him.

The RSUs are scheduled to vest 100% on May 27, 2027, provided he remains in continuous service through that date. After this award, his direct holdings reported in this filing total 1,197,595 shares of common stock, including the shares underlying the RSUs.

Insider Trade Summary

Grant/Award: 8,367 shares

Grant/Award 1 txn

Insider PAPADOPOULOS STELIOS

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8,367	$0.00	$0.00

Holdings After Transaction: Common Stock — 1,197,595 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date.
2. F2. Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs.

Key Figures

RSU grant size: 8,367 units Grant price: $0.00 per share Total holdings after grant: 1,197,595 shares +1 more

4 metrics

RSU grant size 8,367 units Restricted stock units granted on May 27, 2026

Grant price $0.00 per share Non-cash equity compensation award

Total holdings after grant 1,197,595 shares Common stock directly held following reported transaction

Vesting date May 27, 2027 100% of RSUs vest subject to continuous service

Key Terms

restricted stock units, RSUs, 2017 Equity Incentive Plan, continuous service

4 terms

restricted stock units financial

"Represents restricted stock units ("RSUs") granted to the Reporting Person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

2017 Equity Incentive Plan financial

"granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan"

continuous service financial

"The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did EXEL director Stelios Papadopoulos report in this Form 4 for EXEL?

Stelios Papadopoulos reported receiving 8,367 restricted stock units, representing the right to receive an equal number of EXELIXIS common shares. The award is a compensation grant, not an open-market purchase, and carries a zero dollar grant price per share.

How many EXELIXIS (EXEL) shares does Stelios Papadopoulos hold after this RSU grant?

After the reported transaction, Stelios Papadopoulos is shown holding 1,197,595 shares of EXELIXIS common stock directly. This figure includes 8,367 shares that will be issued to him when the newly granted restricted stock units vest, assuming service conditions are satisfied.

When do Stelios Papadopoulos’s EXEL RSUs from this grant vest?

The 8,367 restricted stock units granted to Stelios Papadopoulos are scheduled to vest in full on May 27, 2027. Vesting is conditioned on his continuous service with EXELIXIS through that date under the terms of the 2017 Equity Incentive Plan.

What is the nature of the EXEL award reported by Stelios Papadopoulos?

The filing shows a grant categorized as a “Grant, award, or other acquisition” of restricted stock units. Each RSU is economically equivalent to one EXELIXIS common share and was awarded under the company’s 2017 Equity Incentive Plan as part of director compensation.

Did Stelios Papadopoulos buy or sell EXEL shares in the market in this Form 4?

The Form 4 does not show any open-market buys or sells. Instead, it reports a non-cash grant of 8,367 restricted stock units at a price of $0.00 per share, reflecting equity-based compensation rather than a trading transaction in EXELIXIS stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 05:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAPADOPOULOS STELIOS

(Last) (First) (Middle)

C/O EXELIXIS, INC.

1851 HARBOR BAY PARKWAY

(Street)

ALAMEDA CALIFORNIA 94502

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXELIXIS, INC. [ EXEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		A		8,367(1)	A	$0	1,197,595(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date.

2. Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs.

Remarks:

	/s/ Nina Ayer, Attorney in Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)